512 results on '"Cacciola, Emma"'
Search Results
52. Analysis of common methodological flaws in the highest cited e-cigarette epidemiology research.
53. Ruxolitinib for the Treatment of Polycythemia Vera: Response on Alternative Dose Versus Standard Dose
54. Using stapler in laparoscopic splenectomy does not affect the risk of pancreatic tail injury
55. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19)
56. Effect of Anagrelide on JAK2 Mutational Status in Patients with Essential Thrombocythemia
57. Antiplatelet therapy in essential thrombocythemia: laboratory study of low-dose aspirin
58. D-dimer in the Diagnostic Workup of Suspected Pulmonary Embolism: Additional Clinical Value of Pretest Probability
59. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia
60. Laparoscopic splenectomy: a single center experience
61. Assessment of the efficacy of low-dose aspirin by thromboelastometry in patients with essential thrombocythemia
62. Morning Vs Bedtime Aspirin Intake in Patients with Essential Thrombocyhemia
63. Increased Thromboxane in Patients with Polycythemia Vera and Thrombosis: Evidence for Aspirin-Unsuppressible Platelet Activation In Vivo
64. Idiopathic intramural hematoma of the right colon. A case report and review of the literature
65. Hypereosinophilia and subcutaneous heparin
66. Il timing ottimale dell'introito di aspirina nella trombocitemia essenziale
67. Sopravvivenza libera da trombosi in 734 pazienti con trombocitemia essenziale (WHO 2016) stratificati secondo lo score 'Revised International Prognostic Score for Thrombosis in Essential Thrombocythemia (R-IPSET-Th)'. Studio del Regostro ItalianoTrombocitemie (RIT)
68. Benefit-risk profile of hydroxyurea and antithrombotic treatment after transient ischemic attack or ischemic stroke in myeloprolifertive neoplasms
69. Laboratory responsiveness of low-dose aspirin in patients with essential thrombocythemia
70. Aspirin-treated essential thrombocythemia patients: which timing?
71. Essential thrombocythemia and fibroblast growth factor-2: role of anagrelide
72. Morning Vs Bedtime Aspirin Intake in Patients with Essential Thrombocythemia
73. Preoperative Predictive Factors of Conversions in Laparoscopic Splenectomies
74. Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neolpasms
75. Human platelet antigen genotype: is it a factor for aspirin insensitivity in patient with polycythemia vera?
76. betaFubrinogen G-455-A gene polymorphism: is it a factor for aspirin platelet insensitivity in patients with polycythemia vera?
77. Aspirin-treated essential thrombocythemia patients: which timing?
78. How the Real-Life Diagnostic and Therapeutic Approach Changed in the Last Two Decades in the Thrombocythemic Patients with Ph- Negative Myeloproliferative Neoplasm. Report on 2388 Subjects of the Registro Italiano Trombocitemie (RIT)
79. Aspirin-Platelet Sensitivity in Patients with Polycythemia Vera and Human Platelet Antigen Genotype: Which Are Assays Valid?
80. Relationship between human platelet antigen-1 gene polymorphism and aspirated platelets in patients with essential thrombocythemia
81. The antiphospholipid syndrome in pregnancy: a review article
82. The Antiphospholipid Syndrome
83. Milza
84. Heterozygosity for JAK2V617F is a risk factor of developing post-polycythemia vera myelofibrosis?
85. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neolpasms
86. Jak2 V617F mutation testing in polycythemai vera and polycythemia vera-like disease. Impact on thrombotic risk
87. Elective laparoscopic cholecystectomy
88. Human platelet antigen genotype: Is it a factor for aspirin platelet insensitivity in patients with polycythemia vera?
89. Aspirin-Platelet Sensitivity in Patients with Essential Thrombocythemia: Role βfibrinogen G-455-a Gene Polymorphism
90. Serum overexpresion of interleukin-15 in patients with essential thrombocythemia: which significance?
91. Interleukin-8 levels in essential thrombocythemia: clonal or inflammatory trigger?
92. Effect of heterozygous of JAK2V617F on thrombotic risk in patients with polycythemia vera: measuring the uncertain
93. Interleukin-8 levels in patients with essential thrombocythemia
94. Postsplenectomy Portal Vein Thrombosis: Personal Experience and Review of the Literature
95. Cytoreductive combination therapy in essential trhombocythemia: preliminary report of the Registro Italiano trombocitemia (RIT)
96. Expression of heterozygous or homozygous Jak2V617F in patients with polycythemia vera
97. Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia
98. Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms
99. Declined presentation Human platelet antigen genotype : effect on aspirinated platelets in patients with essential thrombocythemia
100. Late Results After Splenectomy in Adult Idiopathic Thrombocytopenic Purpura
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.